1,632 Shares of Thermo Fisher Scientific Inc. $TMO Acquired by Worth Asset Management LLC

07 Oct 2026, 17:30 by Danessa Lincoln · The Markets Daily

Worth Asset Management LLC purchased a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) during the third quarter, Holdings Channel.com reports. The firm purchased 1,632 shares of the medical research company’s stock, valued at approximately $1,102,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in TMO. BlackRock Inc. purchased a new stake in shares of Thermo Fisher Scientific in the second quarter valued at $15,501,867,000. State Street Corp grew its holdings in shares of Thermo Fisher Scientific by 1.4% during the fourth quarter. State Street Corp now owns 16,613,761 shares of the medical research company’s stock valued at $9,633,991,000 after buying an additional 229,630 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in Thermo Fisher Scientific in the 2nd quarter worth about $1,974,561,000. Bank of America Corp DE acquired a new stake in Thermo Fisher Scientific during the 2nd quarter worth about $1,952,930,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Thermo Fisher Scientific by 0.6% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,428,731 shares of the medical research company’s stock valued at $1,407,328,000 after acquiring an additional 13,728 shares in the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Thermo Fisher Scientific news, VP Lisa P. Britt sold 11,440 shares of the business’s stock in a transaction on Wednesday, August 19th. The shares were sold at an average price of $613.12, for a total transaction of $7,014,092.80. Following the completion of the transaction, the vice president owned 14,784 shares of the company’s stock, valued at $9,064,366.08. The trade was a 43.62% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael D. Shafer sold 25,500 shares of the company’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the sale, the executive vice president owned 20,994 shares of the company’s stock, valued at $12,596,400. This trade represents a 54.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 73,768 shares of company stock valued at $44,122,820 over the last three months. Corporate insiders own 0.33% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on TMO shares. Scotiabank initiated coverage on shares of Thermo Fisher Scientific in a research report on Wednesday, September 9th. They issued an “outperform” rating for the company. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $720.00 price objective on shares of Thermo Fisher Scientific in a research report on Friday, September 25th. Weiss Ratings upgraded shares of Thermo Fisher Scientific from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, August 28th. CLSA assumed coverage on shares of Thermo Fisher Scientific in a report on Thursday, September 3rd. They set an “outperform” rating and a C$748.00 price target on the stock. Finally, Barclays increased their price objective on Thermo Fisher Scientific from $650.00 to $750.00 and gave the stock an “overweight” rating in a report on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $633.13.

Check Out Our Latest Stock Analysis on Thermo Fisher Scientific

Key Thermo Fisher Scientific News

Here are the key news stories impacting Thermo Fisher Scientific this week:

Positive Sentiment: Thermo Fisher’s growth case remains supported by innovation, acquisitions and broad demand across its end markets. The company’s latest quarter exceeded earnings and revenue expectations, while analysts project approximately $25.13 in fiscal 2026 EPS. Is This the Right Time to Add TMO Stock to Your Portfolio?
Positive Sentiment: ClearBridge Investments cited strong third-quarter guidance and broadening demand as reasons for a favorable multi-year outlook, potentially helping explain the rebound following the recent selloff. Strong Q3 Guidance and Broadening Demand Support Multi-Year Outlook
Positive Sentiment: Thermo Fisher’s PPD clinical research business signed an agreement to support Quantum BioPharma’s Phase 2 multiple-sclerosis trial. The contract adds clinical-services revenue potential and reinforces the reach of its pharmaceutical-services platform. Quantum BioPharma Signs Contract with Thermo Fisher
Positive Sentiment: New drug-development and manufacturing offerings showcased at CPHI Milan, including OSD Express, could improve customer adoption and support future growth in biopharma services. Thermo Fisher Showcases New Solutions
Neutral Sentiment: The stock recently reached a new one-year high before retreating, suggesting strong momentum but also increased sensitivity to valuation and profit-taking.
Negative Sentiment: Coverage continues to flag macroeconomic and foreign-currency risks. With TMO trading at a premium earnings multiple, any slowdown in demand or unfavorable currency movements could pressure the shares.

Thermo Fisher Scientific Stock Up 1.4%

Thermo Fisher Scientific stock traded up $9.06 during mid-day trading on Wednesday, hitting $665.64. 860,901 shares of the company’s stock were exchanged, compared to its average volume of 2,246,559. Thermo Fisher Scientific Inc. has a 1-year low of $435.27 and a 1-year high of $694.33. The stock has a 50 day moving average of $622.56 and a two-hundred day moving average of $537.94. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. The stock has a market cap of $246.12 billion, a P/E ratio of 35.85, a P/E/G ratio of 2.83 and a beta of 0.87.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The company had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. During the same quarter in the prior year, the company posted $4.28 EPS. The firm’s revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, analysts anticipate that Thermo Fisher Scientific Inc. will post 25.13 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be given a $0.47 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.11%.

About Thermo Fisher Scientific

(Free Report)

Thermo Fisher Scientific Inc is a global provider of laboratory products, analytical instruments, reagents, consumables, software and services. Its offerings support research, drug discovery and development, clinical diagnostics, biotechnology and pharmaceutical manufacturing, as well as environmental, industrial and other applied markets.

The company’s portfolio includes mass spectrometers, genetic analysis and sequencing systems, electron microscopes, chromatography equipment, laboratory plastics, cell culture products, antibodies, protein and molecular biology reagents, and diagnostic testing solutions.